Search Results
Jul 07, 2026, 07:00 ET Hot Chili Secures US$15 Million Via Amendment Agreement with OR Royalties Inc.
Resource (effective 26 February 2024), which formed the basis of the Preliminary Feasibility Study ("PFS") completed in March 2025 and filed on SEDAR+ on 9 May 2025. The 2023 PEA has been superseded by the 2025 PFS and should no longer be relied upon.Updated Change of Control Buyback prior to
More news about: Hot Chili Limited
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
progression or unacceptable toxicity, whichever occurred first. Efficacy was established based on the dual primary endpoints of progression free survival (PFS) and overall response rate (ORR) determined by Lugano 2014 criteria as assessed by Independent Review Committee (IRC). Additional efficacy outcome measures
More news about: AbbVie
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
progression or unacceptable toxicity, whichever occurred first. Efficacy was established based on the dual primary endpoints of progression free survival (PFS) and overall response rate (ORR) determined by Lugano 2014 criteria as assessed by Independent Review Committee (IRC). Additional efficacy outcome measures
More news about: AbbVie
Jul 02, 2026, 21:01 ET 1911 Gold Issues Clarification of February 2026 PEA Disclosure
Non-CompliantA PEA is, by definition under NI 43-101, a conceptual study of the potential viability of mineral resources. It is not a pre-feasibility study ("PFS") or a feasibility study ("FS") and may not be presented as equivalent to one.These statements are misleading as they convey a level
More news about: 1911 Gold Corporation
Jul 01, 2026, 08:41 ET JFS Wealth Advisors Announces 40th Anniversary Milestone
JFS Wealth Advisors is proud to celebrate its 40th anniversary this year. Founded by Robert C. Jazwinski, CPA/PFS, CFP®, as a single advisor firm back in 1986, when personal financial planning was in its early stages. The predecessor firm evolved with the industry,
More news about: JFS Wealth Advisors
Jun 30, 2026, 17:05 ET First Mining Receives Federal Approval for the Springpole Gold Project Environmental Assessment
First Mining is a gold developer advancing two of the largest gold projects in Canada, the Springpole Gold Project in northwestern Ontario, a PFS-stage project where the federal Environmental Assessment for the Springpole Project was approved in June 2026, and the Duparquet Gold Project in Quebec,
More news about: First Mining Gold Corp.
Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regimen in patients with R/R DLBCL
More news about: AbbVie
Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regimen in patients with R/R DLBCL
More news about: AbbVie
Jun 26, 2026, 16:50 ET SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
therapy or phototherapy, or active psoriatic arthritis. A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available 150 mg PFS and Pen are approved for patients weighing 40 kg or greater. "Plaque psoriasis
More news about: AbbVie
Jun 26, 2026, 07:16 ET Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
is a chemoimmunotherapy regimen used in the treatment of CLL. The primary endpoint is PFS as assessed by blinded IRC. Secondary endpoints include investigator and IRC assessed ORR, duration of response (DoR), and PFS, OS, time to next treatment (TTNT), safety and tolerability and patient-reported outcomes
More news about: Eli Lilly and Company
Jun 25, 2026, 16:34 ET MAYFAIR ANNOUNCES RESULTS OF 2026 ANNUAL GENERAL AND SPECIAL MEETING AND GRANT OF STOCK OPTIONS
Study (the "PFS")1 is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also outlines
More news about: Mayfair Gold Corp.
Jun 25, 2026, 11:23 ET A Drilling Crew, an Icebreaker, and a Path to an Open Pit at Skaergaard
22, 2022 (QP: Philip A. Geusebroek, M.Sc., P.Geo.).[3] Bravo Mining Corp., 2026 Luanga field-season and resource disclosures (PEA July 2025; PFS targeted H2 2026).[4] Chalice Mining Limited, Gonneville palladium-nickel-copper Pre-Feasibility Study, December 2025.[5] Tharisa plc,
More news about: American News Group
Jun 25, 2026, 08:50 ET A Gold Mine Financed in Gold: Lake Victoria Advances One of Tanzania's First Gold-Denominated Project Loans
that development-stage investors often look for.An important caveat applies: although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, those foreign-code studies are not current under Canada's NI 43-101, and the Company has not completed a feasibility study establishing
More news about: USA News Group
Jun 23, 2026, 09:20 ET America Has No Tungsten Mine and a 2027 Deadline -- Now Field Crews Are on the Ground at a Past-Producing Nevada Project
Sangdong commissioning release, March 16, 2026.[5] Guardian Metal Resources plc, Pilot Mountain PFS progress update and NYSE American listing disclosures, March–May 2026.[6] EQ Resources Limited quarterly activities reports
More news about: American News Group
Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe (PFS) to support weight-based dosing for patients weighing less than 40 kg.1 "Plaque psoriasis in children carries its own clinical complexity
More news about: AbbVie
Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe (PFS) to support weight-based dosing for patients weighing less than 40 kg.1 "Plaque psoriasis in children carries its own clinical complexity
More news about: AbbVie
Jun 22, 2026, 15:07 ET SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
iza-bren versus 4.8 months for physician's choice of chemotherapy (Hazard ratio 0.43; 95% CI 0.22 to 0.83). Furthermore, median progression-free survival (PFS) was 8.38 months for iza-bren compared to 4.34 months for chemotherapy (hazard ratio of 0.44; 95% confidence interval 0.32-0.62). At the time of this
More news about: SystImmune, Inc.
Jun 22, 2026, 11:14 ET America's Nuclear Comeback Has a Missing Link: Domestic Fuel -- and Eagle Nuclear Energy Corp. Is Building Across Both Ends
Simulation and Optimization for SMR Program" (GlobeNewswire, June 9, 2026; primary source for the Tensor Medium engagement, SMR program, Aurora resource, PFS timing, CEO Mukhija quote):[2] Eagle Nuclear Energy Corp. — "Provides First Quarter 2026 Corporate Update" (GlobeNewswire, April 15, 2026; de-SPAC
More news about: World Street Intelligence
Jun 22, 2026, 08:02 ET Laboratoires Pierre Fabre erhält die Zulassung der Europäischen Kommission für BRAFTOVI® (Encorafenib) in Kombination mit Cetuximab und FOLFOX (Fluorouracil, Leucovorin und Oxaliplatin) zur Erstlinienbehandlung erwachsener Patienten mit BRAFV600E-mutiertem, em metastasiertem Kolorektalkarzinom (mCRC)
eine statistisch signifikante und klinisch relevante Verbesserung des progressionsfreien Überlebens (PFS) im Vergleich zu einer Oxaliplatin-basierten Chemotherapie mit oder ohne Bevacizumab (medianes PFS 12,8 vs. 7,1 Monate; Hazard Ratio [HR] 0,53; 95 %-Konfidenzintervall [KI], 0,41 bis 0,68; P < 0,001)
More news about: Pierre Fabre Laboratories
Jun 22, 2026, 08:00 ET Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
mFOLFOX6 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with oxaliplatin-based chemotherapy with or without bevacizumab (median PFS 12.8 vs. 7.1 months; hazard ratio [HR] 0.53; 95% confidence interval [CI], 0.41 to 0.68; P<0.001), and
More news about: Pierre Fabre Laboratories
Jun 22, 2026, 08:00 ET Laboratoires Pierre Fabre riceve l'approvazione della Commissione Europea per BRAFTOVI® (encorafenib) in combinazione con cetuximab e FOLFOX (fluorouracile, leucovorin e oxaliplatino) per il trattamento di prima linea di pazienti adulti affetti da carcinoma colorettale metastatico (mCRC) con mutazione BRAFV600E
miglioramento statisticamente significativo e clinicamente rilevante della sopravvivenza libera da progressione (PFS) rispetto alla chemioterapia a base di oxaliplatino, con o senza bevacizumab (PFS mediana 12,8 vs 7,1 mesi; hazard ratio [HR] 0,53; intervallo di confidenza al 95% [CI], da 0,41 a 0,68; P<0,001)
More news about: Pierre Fabre Laboratories
Jun 22, 2026, 07:00 ET Summit Explore Signs Term Sheet for Option and Joint Venture Agreement with NOA Lithium Brines on Arizaro Property in Argentina
immediately preceding the date of delivery of the PEA.Preliminary Feasibility Study ("PFS"). Summit Explore will complete a NI 43-101 compliant PFS and make a cash payment to NOA of USD $2,750,000, both of which are to be completed within 24 months
More news about: Summit Explore Corporation
Jun 22, 2026, 07:00 ET Summit Explore firma una hoja de términos para un acuerdo de opción y empresa conjunta con NOA Lithium Brines en la propiedad de Arizaro en Argentina
valor en nuestra cartera de salmuera de litio", dijo Gabriel Rubacha, director ejecutivo de NOA Lithium Brines Inc. "Mientras Río Grande avanza hacia su PFS, este acuerdo con Summit proporciona un camino para acelerar el avance técnico de Arizaro, nuestro segundo proyecto central, aprovechando los recursos,
More news about: Summit Explore Corporation
Jun 22, 2026, 07:00 ET Silvercorp Announces the Construction Plan and Schedule for the Development of the Chaarat ZAAV Project
from drilling contracts.In 2027, ZAAV plans to complete a PEA and undertake a further 60,000 m of drilling to support a Pre-Feasibility study (PFS), with the objective of submitting the study to the government for review and permitting. The total budget for the year is $15 million.In 2028,
More news about: Silvercorp Metals Inc.
Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
for advanced EGFR-mutant NSCLC following progression on TKI therapy or TKI therapy and platinum-based chemotherapy, and has demonstrated significant PFS and OS benefits in TKI-resistant settings.CHENGDU, China, June 22, 2026
More news about: Kelun-Biotech